Enrolling by invitationPhase 3NCT06549400

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

Studying Proximal myotonic myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lupin Ltd.
Intervention
Mexiletine granules for prolonged-release oral suspension(drug)
Enrollment
176 enrolled
Eligibility
16 years · All sexes
Timeline
20252028

Study locations (6)

Collaborators

Lupin Atlantis Holdings S.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06549400 on ClinicalTrials.gov

Other trials for Proximal myotonic myopathy

Additional recruiting or active studies for the same condition.

See all trials for Proximal myotonic myopathy

← Back to all trials